To ensure consistency between the observed phenotypes due to specific CDK5 inhibition and those observed from cells expressing the PP4R3β S840F variant identified in a melanoma patient, we replaced the endogenous CDK5 with a CDK5-AS variant in the malignant melanoma cell line A375 (Supplementary Fig. 4b). This evidence concerns the gene CDK5 and melanoma.